The biopharma industry ended 2023 with three big-ticket acquisitions in the oncology, autoimmune diseases, radiopharmaceuticals and point-of-care diagnostics spaces.
AstraZeneca last week inked a definitive acquisition agreement with China-based cell therapy biotech Gracell Biotechnologies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,